Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Just Gave Pancreatic Cancer Patients Early Access To A Pill That Doubled Survival Time

The Food and Drug Administration has authorized early expanded access to a new pill called daraxonrasib, developed by Revolution Medicines, giving patients with advanced pancreatic cancer a chance to receive the experimental treatment while it awaits full regulatory approval, in a move the agency completed just two days after receiving the request. Pancreatic cancer is among the most lethal cancers in existence, with a five-year survival rate of only about 3 percent for the most common metastatic form, and until now new treatment options have been frustratingly scarce for patients who have already tried conventional therapies. The speed of the FDA’s response was itself notable: the regulator received Revolution Medicines’ expanded access application on April 28th and signed it on April 30th, and the FDA Commissioner said the two-day turnaround reflects the agency’s commitment to getting promising treatments to patients with life-threatening conditions without delay. The pill works by targeting a protein called RAS, which is mutated in the majority of pancreatic cancer tumors and had for decades been considered essentially undruggable.

In a closely watched phase 3 trial called RASolute 302, daraxonrasib produced results the oncology community called unprecedented: patients taking the pill survived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy, a 60 percent reduction in the risk of death. The drug is taken orally once a day and was generally well tolerated in the trial, with no new safety signals reported. Daraxonrasib has also received Breakthrough Therapy and Orphan Drug designations from the FDA, and the company says it intends to submit a full new drug application under the FDA’s national priority program. Revolution Medicines said it is moving as quickly as possible to ensure safe and equitable access to the drug for eligible patients across the United States.

Source: https://www.reuters.com/legal/litigation/us-fda-authorizes-early-access-revolutions-pancreatic-cancer-pill-2026-05-01/

PrevPreviousCommunities Across America Are Banning AI Data Centers And The Number Just Jumped From 8 To 78
NextA Kitten Found Covered Head To Tail In Industrial Glue Just Made A Full Recovery And Has A New HomeNext

Recent Articles

Happy News

Scientists May Have Finally “Seen” Dark Matter

May 9, 2026

For nearly a century, dark matter has been one of the greatest mysteries in all of science. We know it exists as it makes up an estimated 85% of the universe’s total mass and acts as invisible gravitational scaffolding holding galaxies together, but no one has ever directly observed it.

Read More
Happy News

Coral Reefs Are Hiding An Almost Entirely Unstudied Universe Of Potential Medicine

May 9, 2026

Scientists at the University of Galway and an international consortium have discovered that coral reefs contain an almost entirely unstudied universe of microbial life, publishing a study in Nature that reconstructed the genomes of 645 microbial species from 99 coral reefs across 32 Pacific islands, with more than 99 percent

Read More
Happy News

A Rare Superbloom Is Turning Part Of Redwood National Park Purple And There Are Only Weeks To See It

May 9, 2026

Something extraordinary and fleeting is happening right now in Northern California, where the Bald Hills grasslands above the redwood canopy in Redwood National Park have erupted into a rare lupine superbloom, turning a stretch of elevated landscape off a remote road near Orick into a sweeping sea of purple, blue,

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.